Genetic Engineering Market Companies: Company Analysis, M&A Activity, New Launches, Investment Insights, Recent Industry Trends

 The Genetic Engineering Market Companies sector is making remarkable strides in health, agriculture, and biotechnology, in tandem with cutting-edge innovations and strategic partnerships. This report serves as a guide to the top five companies based on market share, mergers and acquisitions in recent times, any key acquisitions, and new funding in the industry.

Interested in a closer look? Get your hands on a sample copy of this report today! https://www.maximizemarketresearch.com/request-sample/258599/ 

The 5 Companies with the Biggest Market Share

Several key players drive the genetic engineering market, offering innovative solutions and extensive services:

Thermo Fisher Scientific Inc.: As a company with a global reach specializing in scientific research services, this firm provides a multitude of genetic engineering tools, including gene synthesis, sequencing technologies, and CRISPR gene-editing platforms. Their market leadership position is maintained through their focus on research and development.

GenScript Biotech Corporation: Leading provider in gene synthesis, peptide synthesis, and protein engineering. They have gained remarkable market share due to the priority to provide high quality and customizable solutions.

CRISPR Therapeutics AG: The leading company for CRISPR-Cas9 gene-editing technology, CRISPR Therapeutics is focused on advancing new gene-based medicines. This reflects their critical importance in the industry: they are single-handedly tackling diseases of pressing concern by making precise changes in genes.

Merck KGaA (EMD Millipore):Merck KGaA can be viewed as a generalist to advanced genetics, with a broad portfolio including genome editing as well as gene therapy and integrated bioprocessing into its pharmaceutical and biotech portfolio. Their focus on precision medicine and novel research has solidified their market presence (to October 2023).

Roche: One of the leaders in molecular diagnostics and personalized healthcare, Roche applies genetic engineering in developing its diagnostic and therapeutic products. [Genomics and Biotech: Their strategic acquisitions and collaborations have expanded their capabilities in genomics and biotechnology.

Recent Mergers and Acquisitions 

Notable mergers and acquisitions in the genetic engineering sector targeted at expanding technological capabilities and market reach include:

Roche Acts GenMark Diagnostics — $1.8B: Roche Industries acquired GenMark Diagnostics in March 2021, adding the capabilities of their molecular diagnostics network to strengthen Roche's business unit in infectious disease testing.

Roche's Molecular Diagnostics Engine Gears Up: In September 2021, Roche announced that it was expanding its molecular diagnostics engine by acquiring the German biotech group TIB Molbiol, a company known for its expertise in producing reagents for pathogen testing.

Merck Acquires Modifi Biosciences: Merck completed the acquisition of Modifi Biosciences for approximately $1.3 billion in October 2024, in a move to gain access to Modifi's experimental cancer therapies, including the KL-50 class targeting brain tumors, including glioblastomas.

New Market Development

Technical changes and partnerships continue to reshape the industry:

Roche's $2.8 billion partnership with Alnylam Pharmaceuticals: In July 2023, Roche formed a $2.8 billion partnership with Alnylam Pharmaceuticals for a drug targeting hypertension, utilizing Alnylam's RNA interference technology for the treatment of cardiovascular disorders.

Roche Partners with Monte Rosa Therapeutics: In October 2023, Roche collaboration with Monte Rosa Therapeutics to develop and commercialize molecular glue degraders for cancer and neurological diseases through a strategic cooperation and licensing agreement that leverages Monte Rosa's QuEENT platform and Roche's expertise.

New Funding and Investments

The following companies have secured considerable investments that indicate growing optimism about the sector:

Investment in Research Facilities: Thermo Fisher has invested heavily in expanding its research and development facilities, with the goal of advancing innovation in gene editing and synthetic biology.

GenScript Raises Funds for Cell Therapies: GenScript raised money to develop its cell therapies, targeting new cancer and autoimmune disease treatments.

Conclusion

Advancements in technology and strategic collaboration are rapidly transforming the genetic engineering market. Industry giants such as Thermo Fisher Scientific, GenScript Biotech, CRISPR Therapeutics, Merck KGaA, and Roche are continually pushing the boundaries, creating solutions that improve health care, agriculture, and biotechnology. The increasing significance of genetic engineering becomes apparent as recent mergers, acquisitions, and investments continue to shape this innovative sector.

As the sector progresses, stakeholders can expect even greater incorporation of innovative technologies, fueling sustainable practices and addressing the changing demands of the worldwide community.

Get in Touch with Maximize Market Research:

For more information on the Genetic Engineering Market Companies and to access the full report, please contact us:

Maximize Market Research

3rd Floor, Navale IT Park, Phase 2

Pune-Bangalore Highway, Narhe, Pune, Maharashtra 411041, India

Email: [email protected]    

Phone: +91 9607365656